2-Cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide (AGK2) is a strong and potent inhibitor of SIRT2, but has less effect on SIRT1 and SIRT3.273 In HCC, AGK2 increases fibrinogen-like protein 1 (FGL1) acetylation in vitro while decreasing FGL1 protein levels, which are immune checkpoint ligands. Here, FGL1 is linked to hepatocellular carcinoma.